Indication

Treatment of adult patients with advanced hormone-sensitive prostate cancer.

Medicine details

Medicine name:
relugolix (Orgovyx)
SMC ID:
SMC2678
Pharmaceutical company
Accord Healthcare
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
06 August 2024